Ipratropium Bromide Accord (Ipratropium Bromide)

Ipratropium bromide is used to manage respiratory conditions characterized by bronchoconstriction.

• Chronic obstructive pulmonary disease (COPD): Improves airflow and reduces symptoms such as dyspnea.
• Asthma: Provides bronchodilation as an add‑on therapy to improve control of airway narrowing.
• Bronchospasm associated with COPD or asthma: Reduces acute bronchospasm episodes and eases breathing difficulty.

• Ipratropium bromide acts as a competitive antagonist at muscarinic (M1 and M3) acetylcholine receptors on airway smooth muscle. By blocking the action of acetylcholine, it prevents calcium‑mediated contraction, leading to relaxation of bronchial smooth muscle and bronchodilation. The effect is localized to the lungs due to limited systemic absorption after inhalation.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dry mouth: sensation of reduced salivation.
• Cough: transient irritation of the airway.
• Throat irritation: mild soreness or discomfort.
• Hoarseness: temporary change in voice quality.
• Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects

• Paradoxical bronchospasm: worsening of breathing difficulty.
• Allergic reactions: rash, itching, or swelling.
• Angioedema: swelling of face, lips, or tongue.
• Severe eye irritation: if the aerosol contacts eyes.

Before prescribing Ipratropium bromide, clinicians should consider the following precautions.

• Assess renal function: dose adjustment may be needed in severe renal impairment.
• Monitor for worsening respiratory symptoms: discontinue if paradoxical bronchospasm occurs.
• Caution in patients with narrow-angle glaucoma: anticholinergic effects may increase intra‑ocular pressure.
• Avoid use in patients with known hypersensitivity to ipratropium or formulation excipients.
• Use with caution in pregnant or breastfeeding women: benefits should outweigh potential risks.
• Store at room temperature: keep in original container, protect from moisture and heat.

Ipratropium bromide can interact with other medications, affecting efficacy or safety.

Major Interactions (Avoid)

• Beta‑agonist inhalers (e.g., albuterol) when used in excessive doses: may increase risk of cardiovascular side effects.
• Anticholinergic drugs (e.g., atropine): additive anticholinergic effects may lead to dry mouth or urinary retention.

Moderate Interactions (Monitor Closely)

• Antihistamines: may enhance anticholinergic dryness.
• MAO inhibitors: possible increased bronchoconstriction risk.
• Theophylline: monitor for additive bronchodilator effects.